Sun offers $24.50 for Taro shares it doesn't own; Express-Medco deal faces another hearing;

@FiercePharma: Abbott plans to hive off its branded-biopharma business--$18B of its $40B sales--with EVP Richard Gonzalez as CEO News | Follow @FiercePharma

> Sun Pharmaceutical offered $24.50 per share for the remaining stock in Taro Pharmaceutical that it doesn't already own, valuing the company at about $1 billion. Article

> Express Scripts faces another congressional committee hearing on its proposed acquisition of fellow pharmacy benefits manager Medco Health Solutions. Item

> Merck's ($MRK) Irish unit is seeking volunteers to leave its County Wicklow facility, aiming to cut 40 jobs from the payroll. Report

> Perrigo asked FDA to approve its version of the Alcon Labs nasal spray patanase, while Alcon sued the company for patent infringement. Story

> Gilead Sciences ($GILD) breaks ground today on a $140 million R&D facility on its Foster City, CA campus. News

> PPD, the contract research organization that Carlyle Group and Hellman & Friedman want to buy for $3.9 billion, has another interested buyer who's signed a confidentiality agreement in return for more information on the company. Story

Biotech News

@FierceBiotech: Out of the gate yesterday, Sage Tx announces license deal with Ligand for Captisol tech for CNS drugs Item | Follow @FierceBiotech

@JohnCFierce: Thanks to Peter Mueller, Doug Williams, Omid Farokhzad, Tom Hughes and Stephen Knight for an interesting conversation on early stage R&D. | Follow @JohnCFierce

@RyanMFierce: Vertex's Mueller on open R&D: sharing IP gives you an opportunity to solve problems faster. A plug for open R&D? | Follow @RyanMFierce

> Arteaus launches with $18M from Atlas, OrbiMed. Article

> NextBio sees demand for translational research service. Piece

> PwC: Life Science VC funding dips in Q3 2011. Report

Medical Devices News

> Abbott to split into two companies. News

> Gore acquires NMT assets. Item

> Foundation Medicine raises $33.5M in expanded Series A. More

Drug Delivery News

> Santaris wins as delivery partner in Miragen's $352M deal. Article

> Halozyme gets boost from injectable Herceptin. Story

> Topica Pharma grabs $27M B round for topical antifungal drug. Article

> SkyePharma hit with European delay on Flutiform app. Piece

> Scientists find new pulse on gene therapy delivery. More

> Drug-delivery devices could run on power from the body. Report

And Finally... The list of aging-associated proteins known to be involved in cancer is growing longer. Article

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.